StockData
Repligen Corp logo

Repligen Corp (RGEN) company profile

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

About Repligen

Biological Products, (No Diagnostic Substances), SIC 2836

Repligen Corporation is a life sciences company that develops and supplies bioprocessing technologies and systems used in biological drug manufacturing. Its product offerings include filtration products, chromatography solutions, process analytics products, and proteins. These offerings serve customers across the biopharmaceutical and biotechnology industries, specifically supporting operations within the bioprocessing market.

The company is based in the United States, maintaining its corporate headquarters in Waltham, Massachusetts. Repligen conducts international business across multiple geographical markets, with reported commercial operations and regional exposure spanning North America, Europe, and the Asia-Pacific and rest-of-world regions, including entity activity in the Netherlands and Sweden.

Summary of the business section of Repligen's latest annual report, written by StockData.

Company profile

Company

Legal name
Repligen Corp
Founded
1981
Headquarters
Waltham, MA
Address
41 Seyon Street, Building 1, Suite 100 02453
Phone
(781) 449-9560
Employees
2,000, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts, United States

Stock & identifiers

Ticker
RGEN
Exchange
Nasdaq
IPO date
Apr 29, 1986
Shares outstanding
64M, Oct 23, 2026
Public float
$6.00B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
730272
CUSIP
759916109
ISIN
US7599161095
FIGI
BBG000BS48J3
Share class FIGI
BBG001S5VNT9
LEI
54930006QJ0T5AUO1E71
EIN
04-2729386

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Olivier LoeillotChief Executive Officer, Director45,788
Brian Robb DouglassCHIEF PRODUCT OFFICER8,685
Jason K. GarlandCFO18,408
Violetta HughesCHIEF ACCOUNTING OFFICER6,331
Ralf KuriyelSenior VP, R&D20,062
James BylundChief Operating Officer25,423
Manner Carrie EglintonDirector5,461
Rohin MhatreDirector5,014
Martin D. MadausDirector8,392
Karen A. DawesDirector92,816
Nicolas BarthelemyDirector5,436
Glenn P. MuirDirector40,051
Konstantin KonstantinovDirector3,889
Margaret PaxDirector3,011
Anthony HuntDirector89,062

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.11M$8.69M$2.50M$86$125
FY2024
Olivier Loeillot
$7.18M$5.13M$2.24M$156$114
FY2024
Tony JHunt
$20.30M$921.14K$2.24M$156$114
FY2023$7.93M$8.20M$2.78M$194$115
FY2022$7.71M-$14.04M$2.03M$183$111
FY2021$7.77M$28.76M$1.90M$286$125

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Olivier Loeillot
President and Chief Executive Officer
$860.00K$3.37M$1.10M$774.00K$10.29K$6.11M-15%
Jason K. Garland
Chief Financial Officer
$566.50K$1.50M$486.91K$430.19K$5.00K$2.99M+42%
James Bylund
Chief Operating Officer
$481.20K$1.59M$486.91K$365.41K$9.44K$2.93M-30%
Ralf Kuriyel
Senior Vice President, Research and Development
$420.55K$1.21M$365.18K$319.35K$9.21K$2.33M+17%
Brian Douglass
Senior Vice President, Chief Product Officer
$417.15K$912.28K$184.40K$212.75K$8.21K$1.73M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“We have approximately 2,000 employees and operate globally with offices and manufacturing sites located at multiple locations in the United States, Europe and Asia.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?